false 0001623526 0001623526 2023-06-13 2023-06-13





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 13, 2023



Stoke Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)




Delaware   001-38938   47-1144582

(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. Employer

Identification No.)

45 Wiggins Ave

Bedford, Massachusetts

(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code: (781) 430-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.0001 par value per share    STOK    Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company              

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 13, 2023, Stoke Therapeutics, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders and the following proposals were adopted:



Election of three Class I directors, Adrian R. Krainer, Ph.D., Garry E. Menzel, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified:



   Shares For      Shares Withheld/Abstaining      Broker Non-Votes  

Adrian R. Krainer, Ph.D.

     23,672,988        7,986,841        3,838,508  

Garry E. Menzel, Ph.D.

     25,992,037        5,667,792        3,838,508  

Julie Anne Smith

     30,318,661        1,341,168        3,838,508  



Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023:


Shares For


Shares Against


Shares Withheld/Abstaining


  15,863   987



Approval of an amendment to the Company’s Certificate of Incorporation:


Shares For


Shares Against


Shares Withheld/Abstaining


  4,629,558   4,659


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: June 20, 2023     By:  

/s/ Stephen J. Tulipano

      Stephen J. Tulipano
      Chief Financial Officer